Korean stem cells regenerate coach Hiddinks worn-out knee cartilage NOVEMBER 06, 2014 03:02 Korean stem cells regenerate coach Hiddinks worn-out knee cartilage . NOVEMBER 06, 2014 03:02. . Guus Hiddink, the legendary soccer coach who led the Korean national team to the semifinals at the 2002 World Cup Korea-Japan, has been reborn as a figure symbolizing excellence of Korean stem cell treatment. Hiddink, who was suffering from severe arthritis, had his knee cartilage almost completely worn out. Rejecting recommendations to take artificial joint surgery by hospitals in the U.S. and Germany, Hiddink chose to take stem cell treatment in Korea. He started treatment in January this year, and was declared as having fully recovered from the illness 10 months later.

The treatment that gave coach Hiddink a second life is Cartistem, which is made from cord blood stem cells. Cartistem, which was developed by Medipost, a bio venture firm, received product licensure as treatment for knee cartilage that has been damaged due to degenerative conditions and repeated injuries from the Korea Food and Drug Ministry in January 2012. It was the first to receive licensure among stem cell treatments in the world. The treatment is undergoing clinical trials in the U.S. to acquire licensure from the Food and Drug Administration. Despite a highly costly price that is not covered by the national health insurance system, the treatment has been used in more than 1,600 patients thus far.

Stem cell treatments developed in Korea include Hearticellgram, a treatment for cardiac infarction, and Cupistem, a treatment for fistulous opening (a disease that causes holes in tissue between rectums and anus), as well as Cartistem. Hearticellgram and Cupistem use stem cells from tissues of the patients own body. Umbilical cord stem cells and autologous stem cells do not derive from human eggs and hence are free from controversy of bioethics. They are results of steadfast research and investment in stem cells by Korean biotech firms.

In tune with the aging society and a growing number of people with chronic diseases, the bio industry is considered a cash cow industry of the future. Notably, the stem cell sector that treats abnormal bodily organs is the most promising field. Not only bio powerhouses such as the U.S., Japan and the European Union but also China have jumped into the industry. As research on induced pluripotent stem cells (iPS) won the Nobel Prize in physiology and medicine recently, countries worldwide are having mounting interest in the field. The Korean government should create an environment to enable Korean biotech firms to take a leap forward in the global market, by providing generous support for investment and putting in place prompt and predictable licensure and approval process.

The treatment that gave coach Hiddink a second life is Cartistem, which is made from cord blood stem cells. Cartistem, which was developed by Medipost, a bio venture firm, received product licensure as treatment for knee cartilage that has been damaged due to degenerative conditions and repeated injuries from the Korea Food and Drug Ministry in January 2012. It was the first to receive licensure among stem cell treatments in the world. The treatment is undergoing clinical trials in the U.S. to acquire licensure from the Food and Drug Administration. Despite a highly costly price that is not covered by the national health insurance system, the treatment has been used in more than 1,600 patients thus far.

Stem cell treatments developed in Korea include Hearticellgram, a treatment for cardiac infarction, and Cupistem, a treatment for fistulous opening (a disease that causes holes in tissue between rectums and anus), as well as Cartistem. Hearticellgram and Cupistem use stem cells from tissues of the patients own body. Umbilical cord stem cells and autologous stem cells do not derive from human eggs and hence are free from controversy of bioethics. They are results of steadfast research and investment in stem cells by Korean biotech firms.

In tune with the aging society and a growing number of people with chronic diseases, the bio industry is considered a cash cow industry of the future. Notably, the stem cell sector that treats abnormal bodily organs is the most promising field. Not only bio powerhouses such as the U.S., Japan and the European Union but also China have jumped into the industry. As research on induced pluripotent stem cells (iPS) won the Nobel Prize in physiology and medicine recently, countries worldwide are having mounting interest in the field. The Korean government should create an environment to enable Korean biotech firms to take a leap forward in the global market, by providing generous support for investment and putting in place prompt and predictable licensure and approval process.

See the original post:
donga.com[English donga]